Compare DexCom, Inc. (DXCM) vs FirstEnergy Corp. (FE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs FirstEnergy Corp. — how do they compare? DexCom, Inc. trades at $77.62 (market cap $28.06B), while FirstEnergy Corp. trades at $49.2 (market cap $28.13B). The key difference: DexCom, Inc. and FirstEnergy Corp. are close in size by market cap, and FirstEnergy Corp. pays a 3.82% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | FE | |
|---|---|---|
Market Cap | $28.06B | $28.13B |
Sector | Health | Utilities |
52-Week High | $89.53 | $51.91 |
52-Week Low | $54.84 | $40.30 |
Enterprise Value | $27.03B | $56.14B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
FirstEnergy (FE) trades at $49.22, up 1.63% with a bullish technical signal. The stock shows consistent revenue growth, reaching $15.09B in 2025, and maintains a net income margin of 6.86%. Analyst consensus is a Buy with a $52.00 price target, supported by strong cash flow from operations of $3.70B. Recent news highlights growth from data center demand and a $36B investment plan.
Outlook remains positive due to strategic investments and rising energy demand, but risks include high debt levels and regulatory pressures. The stock offers steady growth potential with a dividend yield, though investors should monitor execution of capital expenditures and interest rate impacts on financing costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
